Navigation Links
Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
Date:4/14/2011

line and 6 months are presented below. Although the individual p-values of the cognitive scores did not achieve statistical significance (p < 0.05), all three of these cognitive measures favored the treatment group versus the placebo group.
  • Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog), an average net improvement of 0.41 points in favor of the treatment group versus placebo (p < 0.36)
  • Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB), an average net improvement of 0.38 points in favor of the treatment group versus placebo (p < 0.10)
  • Mini Mental State Examination (MMSE), an average net improvement of 0.19 points in favor of the treatment group versus placebo (p < 0.42)

  • The Estimated Generalized Least Square method(1) was used to calculate a composite cognition score combining each of the secondary cognitive measures (ADAS-Cog, CDR-SOB and MMSE) at baseline and 6 months. The composite cognitive score approached statistical significance, indicating a strong trend toward cognitive benefit favoring the treatment group (p < 0.15).

  • Results reported from Part 2 of this clinical study demonstrated that reaZin was safe and well tolerated by subjects in the treatment group and dropouts were equivalent across the treatment and placebo groups. These results confirm the previously reported results from Part 1 of the clinical study (April 14, 2010) that demonstrated reaZin was well tolerated and superior to Galzin®, an FDA-approved zinc preparation.

A copy of the poster presented at the AAN meeting is available using the following URL: www.adeonapharma.com/AANposter.pdf.

"We are highly encouraged by the results from this clinical study, especially achieving the
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
2. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
3. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
4. Visual Healthcare to Support Chinese Clinical Trials
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant
7. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
8. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
9. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
10. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
11. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), ... for a broad range of cancer types and other conditions, ... , is scheduled to present at the 17 th ... 8-10, 2015 in New York, NY . ... will be presenting at the CNAPS (Circulating Nucleic Acids ...
(Date:9/2/2015)... JUNCTION, N.J. , Sept. 2, 2015 ... immunotherapy leader commercializing its CytoSorb ® blood purification ... around the world, announced that CEO Dr. Phillip ... & Renshaw Annual Global Investment Conference (sponsored by ... 8-10 th in New York City.  ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of the "Pharmaceutical Regulatory ... - October 18-19, 2015)" conference to their ... Compliance with Regulatory Requirements Particularly relevant ... and Document Management Functions & Regulatory Authorities ...
Breaking Medicine Technology:VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015 2VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015 3VolitionRx to Present at Rodman & Renshaw 17th Annual Global Investment Conference in New York and CNAPS IX Conference in Berlin on September 9 and 11, 2015 4CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4Pharmaceutical Regulatory Affairs Course in the Middle East, Dubai (Dubai, UAE - October 18-19, 2015) 2
... , PRINCETON, N.J., Sept. 24 DOR BioPharma, ... a late-stage biotechnology company, announced today that it has entered ... $3.85 million. DOR,s North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., ... Under the terms of the agreements, DOR will sell approximately ...
... Sept. 24 Cephalon, Inc. (Nasdaq: CEPH ) ... granted a priority review for its supplemental New Drug Application ... in June of this year. The FDA decision on approval ... with excessive sleepiness associated with jet lag disorder due to ...
Cached Medicine Technology:DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 2DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 3DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors 4Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 4
(Date:9/2/2015)... , ... September 02, 2015 , ... ... combining both naturopathic and allopathic medicine, opens its second location this week at ... features roughly 1000 square feet of lounge space for patients to relax while ...
(Date:9/2/2015)... , ... September 02, 2015 ... ... nation’s largest and fastest-growing interim clinical staffing companies, has completed a recapitalization ... Group.         , BPOC and Heritage Group each offer extensive expertise ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... announced today. The two day international investment and business conference will be hosted ... 2015 in Beijing China. The full-weekend networking conference will feature leading EB-5 industry ...
(Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., a leading ... and services to both government and commercial clients, today announced the release of ... IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances the images ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... the University of East Anglia have found that gold ... particles they say reveal the presence of poisons far ... back to a lab. This they hope would help ... led by Professor David Russell use of gold nanoparticles ...
... health care despite the fact that health care expenditure ... the results of a multi-national survey that was concluded ... that United States had spent $6,280 per capital on ... countries. ,US patients reported more diagnostic errors, ...
... out of 800 samples sent to a lab from ... for bird flu, official sources say.//, ,The samples ... sent till March 17 from Burhanpur, Barwani, Khargone, Jhabua, Balaghat, ... shadow of bird flu that broke out in Jalgaon district ...
... New Delhi. The Delhi High Court Monday issued notice ... Delhi government on a public interest litigation seeking legal// ... through a repeal of section 377 of the Indian ... is a criminal offence and punishable with imprisonment up ...
... Women approaching menopause are likely to face depression, says a ... treatment.//, ,Depression is a substantial illness with significant morbidity ... that can be managed, reports the health portal WebMd. , ... Massachusetts General Hospital studied 460 Boston women aged 36 to ...
... it has been found that if there is Intrahepatic cholestasis ... on.// ,This case control study was performed ... result. Intrahepatic cholestasis of pregnancy (ICP) is an itchy skin ... ,The study is published in the April 2006 issue ...
Cached Medicine News:Health News:Gold Nanoparticles Are Good Detectors Biological Toxins 2Health News:Intrahepatic cholestasis during pregnancy predisposes to later liver disease 2
...
...
... At the entry-level, Philips Zymed 1810 Series ... preview, which gives the operator the flexibility ... complex arrhythmia. Choose an application beyond the ... flexibility. Select the interactive or automatic style ...
... Zymed 2010 plus Holter Software for ... application as easy to install, use ... data presentation as comprehensive as a ... superimposition, prospective paging and QuickScan, which ...
Medicine Products: